西地那非治疗硬皮病早期肺血管疾病 (SEPVADIS)
This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective treatment for SSc-MEP.
研究概览
地位
地位
干预/治疗
干预/治疗
详细说明
Data shows that sildenafil (SIL) is an effective therapy in SSc-PAH. SIL has been safely used in many patients with various vascular and cardiovascular diseases over the past three decades. Randomized controlled trial data for SIL shows improvement in 6MWD, hemodynamics, and even evidence of cardiac remodeling in PAH and SSc-PAH patients. Based upon these data, SIL may be an effective therapy in SSc-MEP. This study will help determine whether sildenafil could be a good treatment for patients with scleroderma that have mildly elevated pulmonary pressures.
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 阶段2
联系人和位置
学习联系方式
学习联系方式
- 姓名:Stephen Mathai, MD
- 电话号码:4106146311
- 邮箱:smathai4@jhmi.edu
研究联系人备份
- 姓名:Renee Ofori
- 电话号码:410-614-6311
- 邮箱:rofori2@jhu.edu
学习地点
-
-
Louisiana
-
New Orleans、Louisiana、美国、70806
- 尚未招聘
- Louisiana State University
-
首席研究员:
- Matthew Lammi, MD
-
接触:
- Matthew Lammi, MD
- 电话号码:504-568-4634
-
接触:
- Marie Sandi
- 邮箱:mchild@lsuhsc.edu
-
-
Maryland
-
Baltimore、Maryland、美国、21287
- 招聘中
- Johns Hopkins
-
接触:
- Dezeray Dutton
- 电话号码:4435078222
- 邮箱:dcephas1@jhu.edu
-
接触:
- Stephen Mathai, MD
- 电话号码:410-614-6311
- 邮箱:smathai4@jhmi.edu
-
首席研究员:
- Stephen Mathai, MD
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Previous documentation of mean pulmonary artery pressure between 21 and 24 mm Hg with a pulmonary capillary wedge pressure (or left ventricular end-diastolic pressure) ≤ 15 mm Hg within six months before study entry.
- Diagnosis of SSc according to 2013 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) classification criteria.
- Pulmonary function tests with forced expiratory volume in one second/forced vital capacity (FEV1/FVC) >50% AND either a) total lung capacity (TLC) or forced vital capacity (FVC) > 70% predicted or b) TLC or FVC between 60% and 70% predicted with no more than mild interstitial lung disease on computerized tomography scan of the chest on studies obtained within 6 months of enrollment.
- Ventilation perfusion scan or computed tomography with intravenous contrast (CT angiogram) without evidence of chronic thromboembolism at anytime before study entry.
- Ability to perform six minute walk testing without significant limitations in musculoskeletal function or coordination.
- Informed consent.
Exclusion Criteria:
- World Health Organization (WHO) Class IV functional status.
- Systolic blood pressure less than 90 mmHg at screening visit prior to enrollment.
- Clinically significant untreated sleep apnea.
- Left-sided valvular disease (more than moderate mitral valve stenosis or insufficiency or aortic stenosis or insufficiency), pulmonary artery or valve stenosis, or ejection fraction < 45% on most recent echocardiography (within 1 year).
- Use of Pulmonary Arterial Hypertension (PAH) therapy (prostacyclin analogues, endothelin-1 receptor antagonists,phosphodiesterase-5 inhibitors, riociguat, selexipag) within the past 3 months.
- Hospitalized or acutely ill.
- Renal failure (creatinine above 2.0) at screening visit.
- Enrollment in a clinical trial or concurrent use of another investigational drug (non FDA approved) or device therapy within 30 days of screening visit.
- Age < 18.
- Currently pregnant.
- Current use of nitrates.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:Sildenafil
Sildenafil 20 mg by mouth three(3) times each day |
Sildenafil 20 mg three times a day. This is the approved dose for the treatment of pulmonary arterial hypertension. It is being studied in this trial with a population who has mildly elevated pulmonary pressures.
其他名称:
|
|
安慰剂比较:Placebo
Placebo by mouth three(3) times each day |
Oral pill placebo. |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Difference in change in distance walked in 6 minute walk test (6MWT) at 4 months
大体时间:Baseline and 4 months
|
As assessed by change in 6 minute walk distance (6MWD) in feet (from baseline to 4 months) between the sildenafil group and the placebo group. |
Baseline and 4 months
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Difference in change in distance walked in 6MWT at 12 months
大体时间:Baseline and 12 months
|
As assessed by change in 6 minute walk test distance in feet (from baseline to 12 months) between the sildenafil group and the placebo group. |
Baseline and 12 months
|
|
Difference in change in right ventricular function as assessed by cardiac MRI
大体时间:Baseline and 4 months
|
As assessed by change in right ventricular function (normal/abnormal) on cardiac MRI. |
Baseline and 4 months
|
|
Difference in change in right ventricular function as assessed by cardiac MRI
大体时间:Baseline and 12 months
|
As assessed by change in right ventricular function (normal/abnormal) on cardiac MRI. |
Baseline and 12 months
|
|
Difference in change in right ventricular function as assessed by invasive hemodynamics
大体时间:Baseline and 4 months
|
As assessed by change in right ventricular function (normal/abnormal) on invasive hemodynamics. |
Baseline and 4 months
|
|
Difference in change in right ventricular function as assessed by invasive hemodynamics
大体时间:Baseline and 12 months
|
As assessed by change in right ventricular function (normal/abnormal) on invasive hemodynamics. |
Baseline and 12 months
|
|
Difference in change in right ventricular function as assessed by echocardiography
大体时间:Baseline and 4 months
|
As assessed by change in right ventricular function (normal/abnormal) on echocardiography. |
Baseline and 4 months
|
|
Difference in change in right ventricular function as assessed by echocardiography
大体时间:Baseline and 12 months
|
As assessed by change in right ventricular function (normal/abnormal) on echocardiography. |
Baseline and 12 months
|
|
Difference in change in N-terminal pro b-type natriuretic peptide level
大体时间:Baseline, 4 months and 12 months
|
As assessed by changes in plasma N-terminal pro b-type natriuretic peptide (NT-proBNP) level (pg/mL) between sildenafil and placebo groups at four months and twelve months. |
Baseline, 4 months and 12 months
|
|
Difference in change in health related quality of life as assessed by the 36-Item Short Form Health Survey (SF36) questionnaire
大体时间:Baseline, 4 months and 12 months
|
As assessed by changes in SF36 questionnaire between sildenafil and placebo groups at four months and twelve months. The SF36 yields a set of scaled scores in 8 domains, with higher numbers representing a better quality of life. Each scale is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible score achieved. In step 2, items in the same scale are averaged together to create the 8 scale scores. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Hence, scale scores represent the average for all items in the scale that the respondent answered. |
Baseline, 4 months and 12 months
|
|
Difference in change in health related quality of life as assessed by the emPHasis-10 health-related quality of life questionnaire (emPHasis-10).
大体时间:Baseline, 4 months and 12 months
|
As assessed by changes in emPHasis-10 questionnaire between sildenafil and placebo groups. The Emphasis 10 score consists of 10 questions scored in a semantic 6-point scale (from 0 to 5), for a total maximum score of 50 (the higher the score, the worse the quality of life). |
Baseline, 4 months and 12 months
|
|
Difference in safety profile as assessed by frequency of adverse events
大体时间:Ongoing until study closes, up to 4 years
|
As assessed by frequency of adverse events between sildenafil and placebo groups. |
Ongoing until study closes, up to 4 years
|
|
Difference in safety profile as assessed by severity of adverse events
大体时间:Ongoing until study closes, up to 4 years
|
As assessed by severity of adverse events between sildenafil and placebo groups. |
Ongoing until study closes, up to 4 years
|
合作者和调查者
合作者
合作者
调查人员
调查人员
- 首席研究员:Stephen Mathai, MD、Johns Hopkins University
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
其他研究编号
- IRB00265164
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.